Skip to content

Study · Not a test of the peptide alone · 2025

1 result

[A clinical case of treating a patient with severe ischemic stroke and cancer].

Marchenko SV, Hil IH, Hil UV, Smolskaya NY

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2025

PMID40879237 (opens in a new tab)DOI10.17116/jnevro2025125081114 (opens in a new tab)PepBankPUB-40879237
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome

    In a patient with stroke and cancer, rehabilitation with adjunctive Cerebrolysin reduced neurological deficits.

    In plain wordsIn a patient with stroke and cancer, rehabilitation with Cerebrolysin reduced neurological deficits.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNeurological deficits
    Study

    n = 1

    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    Baseline NIHSS
    20
    Before rehabilitation and adjunctive Cerebrolysin, neurological deficit reduction

    Source sentences

    Summary
    Early comprehensive rehabilitation and adjunctive therapy with Cerebrolysin (30 ml/day) significantly reduced neurological deficits.
    Summary
    The patient was admitted to the hospital in the hyperacute stage of ischemic stroke due to thrombosis of the left middle cerebral artery, complicated by severe global aphasia and right-sided hemiplegia (NIHSS - 20).
    1 context sentence
    Summary · context
    We present a clinical case of cancer-associated ischemic stroke in a 70-year-old patient with metastatic sigmoid colon cancer.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.